Reducing Postoperative Recurrence of Early‐Stage Hepatocellular Carcinoma by a Wound‐Targeted Nanodr...
Reducing Postoperative Recurrence of Early‐Stage Hepatocellular Carcinoma by a Wound‐Targeted Nanodrug
About this item
Full title
Author / Creator
li, Bozhao , Zhang, Xiuping , Wu, Zhouliang , Chu, Tianjiao , Yang, Zhenlin , Xu, Shuai , Wu, Suying , Qie, Yunkai , Lu, Zefang , Qi, Feilong , Hu, Minggen , Zhao, Guodong , Wei, Jingyan , Zhao, Yuliang , Nie, Guangjun , Meng, Huan , Liu, Rong and Li, Suping
Publisher
Germany: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Germany: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
New strategies to decrease risk of relapse after surgery are needed for improving 5‐year survival rate of hepatocellular carcinoma (HCC). To address this need, a wound‐targeted nanodrug is developed, that contains an immune checkpoint inhibitor (anti‐PD‐L1)and an angiogenesis inhibitor (sorafenib)). These nanoparticles consist of highly biocompatib...
Alternative Titles
Full title
Reducing Postoperative Recurrence of Early‐Stage Hepatocellular Carcinoma by a Wound‐Targeted Nanodrug
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_dbec8c8301d14fb9b9e65f5f4383ac7d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_dbec8c8301d14fb9b9e65f5f4383ac7d
Other Identifiers
ISSN
2198-3844
E-ISSN
2198-3844
DOI
10.1002/advs.202200477
